TAP vs ZVRA · rev $13.04B vs P/E 6.3, rev $75.9M
TAP (TAP) versus Zevra Therapeutics Inc. (ZVRA) — a side-by-side from cached financials, not a winner call.
TAP (TAP) common stock.
Zevra Therapeutics Inc. (ZVRA) is a biotechnology company listed on NASDAQ.
Latest reported TAP revenue for 2025-12-31 was $13.04B. Net income was -$2.14B. Revenue was down 5.1% from 2024-12-31 to 2025-12-31. TAP currently screens at market cap $0.
Latest reported ZVRA revenue for 2026-06-30 was $75.9M. Net income was $46.6M. ZVRA currently screens at market cap $745.4M and trailing P/E 6.3.
TAP currently screens at market cap $0. ZVRA currently screens at market cap $745.4M and trailing P/E 6.3.
Not investment advice. Open the TAP and ZVRA stock pages for the full models.
Not investment advice.